Inside U.S. Regulations

Covering Class I Recall, FDA Approval, Monetary Judgment, Vaccines, DEA Registration. Key updates on Class I Recall of medical syringes, FDA approval under priority voucher, FTC monetary judgment, upcoming vaccine advisory committee, and DEA rescheduling for medical marijuana registrations.

Show Notes

This episode covers pivotal regulatory news affecting multiple sectors including Class I recalls, FDA approvals under priority programs, monetary judgments by the FTC, vaccine advisory committee activities, and DEA registration changes for medical marijuana.

Notably, Medical Action Industries issued a Class I Recall on convenience kits containing Namic RA syringes due to risks of serious injury from adaptor disconnections. Customers must quarantine affected products and update warning labels.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene to review the COVID-19 vaccine formula for the upcoming season, with public participation and comment deadlines outlined.

The DEA has rescheduled FDA-approved marijuana products from Schedule I to Schedule III, creating an expedited registration process that requires businesses to maintain state licenses alongside federal compliance.

For more information, visit the Carver Agents website.

Articles mentioned:
  1. OAI / SBG / SB OAI JV
  2. Fixing Failures to Communicate
  3. Vaccines and Related Biological Products Advisory Committee Meeting May 28, 2026 Announcement
  4. Convenience Kit Recall: Medical Action Industries Removes Convenience Kits Containing Namic RA Syringes
  5. Americana Liberty, FTC v. (timeline item)
  6. Typhoon Sinlaku Communications Status Report – May 3, 2026
  7. U.S. Supreme Court Issues Temporary Stay on Restrictions on Mifepristone after Attorney General Rayfield and Coalition File Brief
  8. Attorney General Bonta Urged U.S. Supreme Court to Protect Telehealth Access to Mifepristone
  9. Industry Bulletin 26:05 - 05/04/26 - Attorney General Rescheduling Order
  10. FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

What is Inside U.S. Regulations?

Regulatory news, updates, and insights for USA presented by the Carver Agents team

Welcome to Carver's USA Regulatory Updates for May 10, 2026.

The U.S. Food and Drug Administration announced that its Vaccines and Related Biological Products Advisory Committee, or VRBPAC, will meet on May 28, 2026. The committee will review and recommend the COVID-19 vaccine formula for the 2026-2027 season. Stakeholders may participate via online teleconference or webcast. Public comments must be submitted by May 27, 2026, to docket FDA-2026-N-3962. Requests to make oral presentations are due by May 18, 2026, with notifications by May 20, 2026.

In medical device news, Medical Action Industries has issued a Class I Recall on convenience kits containing Namic RA syringes. The syringes’ rotating adaptor may unwind, causing loose connections or disconnections that could lead to biohazard exposure, blood loss, infection, air embolism, serious injury, or death. Customers are advised to identify, segregate, and quarantine all affected products. Revised warning labels must be applied prominently, and distributors or resellers notified of the recall.

The U.S. Federal Trade Commission has entered a permanent injunction against Americana Liberty, prohibiting false or misleading 'Made in USA' or country of origin claims. The defendants must comply with specific labeling and disclosure requirements for Textile Fiber Products. A monetary judgment of two million dollars was entered, with partial suspension contingent on truthful financial disclosures.

The Federal Communications Commission reported activation and expansion of the Disaster Information Reporting System, or DIRS, for the Commonwealth of the Northern Mariana Islands and Guam following Typhoon Sinlaku. Waivers and special temporary authorities have been granted to support emergency communications and service restoration. Facilities-based mobile wireless providers are required to provide reasonable roaming under disaster arrangements when feasible, activate mutual aid agreements, and enhance municipal preparedness and public awareness.

In federal court developments, the U.S. Supreme Court issued a temporary administrative stay on the Fifth Circuit’s ruling that would reinstate an in-person dispensing requirement for mifepristone. This stay allows continued telehealth access to the medication abortion drug. The stay follows a brief filed by Attorney General Rob Bonta of California and coalition partners urging protection of telehealth access. The FDA’s 2023 decision permitting telehealth dispensing remains in effect.

On May 4, 2026, Attorney General Rob Bonta of California publicly urged the U.S. Supreme Court to maintain telehealth access to mifepristone without in-person dispensing requirements.

The Drug Enforcement Administration has implemented a federal rescheduling order moving FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III. This change establishes an expedited DEA registration process for eligible entities. To participate, businesses must maintain their state-issued medical marijuana license and apply for DEA registration using that license as evidence. Compliance with both federal and state regulations remains mandatory, as DEA registration does not replace state licensing.

Finally, the U.S. Food and Drug Administration granted the seventh approval under its National Priority Voucher Pilot Program to Bizengri, a treatment for an ultra-rare cancer. Manufacturers must comply with FDA safety monitoring for serious side effects and participate in public feedback processes related to the pilot program.

That wraps up today's regulatory updates. Visit carveragents.ai for more information.